pharmaphorum

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage small ...
ascopubs.org

IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant ...

Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial. This is an ASCO Meeting ...
FierceBiotech

Patient deaths prompt partial hold for Daiichi-Merck's global phase 3 ADC program

Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. “Due ...
Technical

Ideate just launched its first product — and plans a $500k pre-seed round by year’s end

For local founder Rahmi Halaby, launching his company’s product to the public is the catalyst for its next phase of growth. Halaby’s company, Ideate, officially launched its first product — a platform ...
EurekAlert!

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

(Barcelona, Spain. September 7, 2025 at 4:45 PM CEST / UTC +2 )--Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ...
Business Wire

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Data from IDeate-Lung01 trial will be presented at upcoming IASLC 2025 World Conference on Lung Cancer First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s ifinatamab deruxtecan based ...
Pharmabiz

IDeate-Prostate01 phase 3 clinical trial of ifinatamab deruxtecan began in patients with pretreated metastatic castration-resistant prostate cancer

The first patient has been dosed in the IDeate-Prostate01 phase 3 clinical trial to evaluate the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...
Nasdaq

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab ...
ascopubs.org

IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors.

Body composition modulations during cyclic fasting-mimicking diet in patients with advanced solid cancers. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Pharmabiz

IDeate-Esophageal01 phase 3 trial of ifinatamab deruxtecan initiated in certain patients with pretreated advanced or metastatic ESCC

The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of ...
cmu.edu

IDeATe at 10: Celebrating a Decade of Collaborative Innovations

The most valuable treasures are often buried. So, it should come as no surprise that IDeATe(opens in new window) (Integrative Design, Arts and Technology), a wildly sought-after interdisciplinary ...